Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Aline Talhouk(University of British Columbia), Chloe Karpinskyj(Breast Cancer Now), Jesús García-Donás(Universidad San Pablo CEU), Derek S. Chiu(University of British Columbia), Billy Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tuan Zea Tan(National University Cancer Institute, Singapore), Timothy Budden(University of Manchester), Michael E. Carney(The University of Texas MD Anderson Cancer Center), Kara L. Cushing‐Haugen(Fred Hutch Cancer Center), Amy Lum(University of British Columbia), Brenda Y. Hernandez(Cancer Center of Hawaii), C. Blake Gilks(Vancouver General Hospital), Clara Bodelón(American Cancer Society), Rosalind Glasspool(Institut Bergonié), Joshy George(Jackson Laboratory), Samuel C.Y. Leong(Vancouver General Hospital), Teodora Goranova(AstraZeneca (United Kingdom)), Mila Volchek(Royal Women's Hospital), Casey S. Greene(University of Colorado Anschutz Medical Campus), Aleksandra Gentry‐Maharaj(UCL Australia), Sabine Behrens(German Cancer Research Center), Joy Hendley(Peter MacCallum Cancer Centre), Sián Fereday(Peter MacCallum Cancer Centre), Renée T. Fortner(Norwegian Institute of Public Health), Stefan Kommoss, Holly R. Harris(Fred Hutch Cancer Center), Susana Banerjee(Royal Marsden NHS Foundation Trust), Maria P. Intermaggio(The University of Melbourne), Yoke-Eng Chiew(The University of Sydney), Wafaa Elatre(Keck Hospital of USC), Louise A. Brinton(National Cancer Institute), Robertson Mackenzie, Geyi Liu(Vancouver General Hospital), Rex C. Bentley(Duke University), Alison H. Brand(The University of Sydney), Esther Herpel(Memorial Sloan Kettering Cancer Center), Tayyebeh M. Nazeran(BC Cancer Agency), Janine Senz(University of British Columbia), Hanwei Sudderuddin(University of British Columbia), Cezary Cybulski(International Hereditary Cancer Center), Paul Haluska(Mayo Clinic in Arizona), Darren Ennis, Chen Wang(Xiamen University), Stephanie Chen(Rutgers, The State University of New Jersey), Huei San Leong(Peter MacCallum Cancer Centre), Veronica Chow(Vancouver General Hospital), Mercedes Jimenez‐Liñan(University of Kansas), Dustin Johnson(Vancouver General Hospital), Jennifer Alsop(Manchester Academic Health Science Centre)
Cited by 79
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k